Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus

Oxidative Medicine and Cellular Longevity

Volumn 3, Issue 5, 2010, Pages 325-331

  Réus, Gislaine Z ^a   Stringari, Roberto B ^a   De Souza, Bruna ^a   Petronilho, Fabrícia ^a   Dal Pizzol, Felipe ^a   Hallak, Jaime E ^b   Zuardi, Antônio W ^b   Crippa, José A ^b   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antioxidants activity; Depression; Harmine; Imipramine; Reactive oxygen species

Indexed keywords

ANTIOXIDANTS ACTIVITY; DEPRESSION; HARMINE; IMIPRAMINE; REACTIVE OXYGEN SPECIES;

DISEASES; OXIDATION; PROTEINS;

OXYGEN;

CATALASE; HARMINE; IMIPRAMINE; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HIPPOCAMPUS; LIPID OXIDATION; MALE; NONHUMAN; OXIDATION; PREFRONTAL CORTEX; PROTEIN OXIDATION; RAT; TREATMENT DURATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CATALASE; DEPRESSION; HARMINE; HIPPOCAMPUS; IMIPRAMINE; MALE; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

RATTUS;

EID: 78650734801     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.4161/oxim.3.5.13109     Document Type: Article

References (45)

1. Frey BN, Valvassori SS, Réus GZ, Martins MR, Petronilho FC, Bardini K, et al. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res 2006; 31:699-703.
2. Frey BN, Valvassori SS, Réus GZ, Martins MR, Petronilho FC, Bardini K, et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006; 31:326-32.
3. Kodydková J, Vávrová L, Zeman M, Jirák R, Macášek J, Staňková B, et al. Antioxidative enzymes and increased oxidative stress in depressive women. Int J Neuropsychopharmacol 2008; 11:851-76.
4. Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresér KM, Gomes FA, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1677-81.
5. Lucca G, Comim CM, Valvassori SS, Réus GZ, Vuolo F, Petronilho F, et al. Increased oxidative stress in submitochondrial particles into the brain of rats submitted to the chronic mild stress paradigm. J Psych Res 2009; 43:864-9.
6. Lucca G, Comim CM, Valvassori SS, Réus GZ, Vuolo F, Petronilho F, et al. Effects of chronic mild stress on the oxidative parameters in the rat brain. Neurochem Int 2009; 54:358-62.
7. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11:851-76.
8. Riegel RE, Valvassori SS, Elias G, Réus GZ, Steckert AV de Souza B, et al. Animal model of mania induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int 2009; 55:491-5.
9. Wood SJ, Yücel M, Pantelis C, Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore 2009; 38:396-406.
10. Floyd RA. Antioxidants, oxidative stress and degenerative neurological disorders. Proc Soc Exp Biol Med 1999; 222:236-45.
11. Bilici M, Efe H, Koroglu MA, Uydu HÁ, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disorders 2001; 64:43-51.
12. Michel TM, Frangou S, Thiemeyer D, Camara S, Jecel J, Nara K, et al. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder-a postmortem study. Psychiat Res 2007; 151:145-50.
13. Tretter L, Chinopoulos C, Adam-Vizi V. Enhanced depolarization-evoked calcium signal and reduced [ATP]/[ADP] ratio are unrelated events induced by oxidative stress in synaptosomes. J Neurochem 1997; 69:2529-37.
14. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nature Rev Neurosc 2006; 7:137-45.
15. Castrén E. Is mood chemistry? Nat Rev Neurosc 2005; 6:241-6.
16. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54:597-606.
17. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34:13-25.
18. Farzin D, Mansouri N. Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test. Eur Neuropsychopharmacol 2006; 16:324-8.
19. Fortunato JJ, Réus GR, Kirsch TR, Stringari RB, Fries GR, Kapczinski F, et al. Effects of Beta-carboline harmine on behavioural and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties. Brain Res Bull 2010; 81:491-6.
20. Fortunato JJ, Réus GZ, Kirsch TR, Stringari RB, Stertz L, Kapczinski F, et al. Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1425-30.
21. Kim H, Sablin SO, Ramsay RR. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 1997; 337:137-42.
22. Glennon RA, Dukat M, Grella B, Hong S, Costantino L, Teitler M, et al. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend 2000; 60:121-32.
23. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-Methyl-D-Aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008; 28:631-7.
24. Duman RS, Monteggia LM. A Neurotrophic Model for Stress-Related Mood Disorders. Biol Psychiatry 2006; 59:1116-27.
25. Hall J, Whalley HC, Marwick K, McKirdy J, Sussmann J, Romaniuk L, et al. Hippocampal function in schizophrenia and bipolar disorder. Psychol Med 2009; 7:1-10.
26. Maiese K. High anxiety: recognizing stress as the stressor. Oxid Med Cell Longev 2009; 2:61-2.
27. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev 2009; 2:63-7.
28. Eren I, Naziroǧlu M, Demirdas A, Celik O, Uǧuz AC, Altunbasak A, et al. Venlafaxine modulates depressioninduced oxidative stress in brain and medulla of rat. Neurochem Res 2007; 32:497-505.
29. Fontella FU, Siqueira IR, Vasconcellos AP, Tabajara AS, Netto CA, Dalmaz C. Repeated restraint stress induces oxidative damage in rat hippocampus. Neurochem Res 2005; 30:105-11.
30. Liu J, Wang X, Shigenaga MK, Yeo HC, Mori A, Ames BN. Immobilization stress causes oxidative damage to lipid, protein and DNA in the brain of rats. FASEB J 1996; 10:1532-8.
31. Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol Clin Exp 2009; 24:277-86.
32. Muñoz-Castañeda JR, Montilla P, Padillo FJ, Bujalance I, Muñoz MC, Muntané J, et al. Role of serotonin in cerebral oxidative stress in rats. Acta Neurobiol Exp (Wars) 2006; 66:1-6.
33. Mokoena ML, Harvey BH, Oliver DW, Brink CB. Ozone modulates the effects of imipramine on immobility in the forced swim test and nonspecific parameters of hippocampal oxidative stress in the rat. Metab Brain Dis 2010; 25:125-33.
34. Kumar A, Garg R, Gaur V, Kumar P. Nitric oxide mechanism in protective effect of imipramine and venlafaxine against acute immobilization stress-induced behavioral and biochemical alteration in mice. Neurosci Lett 2009; 467:72-5.
35. Júnior HV, de França Fonteles MM, Mendes de Freitas R. Acute seizure activity promotes lipid peroxidation, increased nitrite levels and adaptative pathways against oxidative stress in the frontal córtex and striatum. Oxid Med Cell Longev 2009; 2:130-7.
36. Kumar A, Garg R. Possible role of trazodone and imipramine in sleep deprivation-induced anxiety-like behavior and oxidative damage in mice. Methods Find Exp Clin Pharmacol 2009; 31:383-7.
37. Zafir A, Ara A, Banu N. Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsycho pharma col Biol Psychiatry 2009; 33:220-8.
38. Kim DH, Jang YY, Han ES, Lee CS. Protective effect of harmaline and harmalol against dopamine and 6-hydroxydopamine-induced oxidative damage of brain mitochondria and synaptosomes and viability loss of PC12 cells. Euro J Neurosci 2001; 13:1861-72.
39. Garcia LB, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psych 2008; 32:140-4.
40. Paxinos G, Watson C. The rat brain: stereotaxic coordinates. Second Ed. Australia: Academic Press 1986.
41. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymo 1990; 186:407-21.
42. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994; 233:346-57.
43. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105:121-6.
44. Bannister JV, Calabrese L. Assays for superoxide dismutase. Methods Biochem Anal 1987; 32:279-312.
45. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-75.